The cutoffs used for tumor markers were based on institutional criteria, and prospective studies are warranted to elucidate precise cutoffs to predict the effect of anti-PD-1/PD-L1 antibodies and to confirm the utility of serum CYFRA 21-1 level across different clinical settings. This evidence concerns the gene CD274 and neoplasm.